Schlosser Mario 4
Research Summary
AI-generated summary
Oscar Health (OSCR) Director Mario Schlosser Sells Shares
What Happened
- Director Mario Schlosser converted 47,500 Class B/derivative shares into Class A common stock and, on the same date (July 1, 2026), sold 47,500 shares in three open-market transactions. Total cash proceeds from the sales were approximately $1,484,014.
- Sales breakdown: 3,600 shares at $29.50 ($106,200); 13,672 shares at $30.80 ($421,098); 30,228 shares at $31.65 ($956,716). The conversion entries show no cash was exchanged for the derivative-to-equity conversion.
Key Details
- Transaction date: July 1, 2026 (report filed July 6, 2026; Period of Report 2026-07-01).
- Proceeds: ~$1,484,014 total; weighted average price across the 47,500 sold shares ≈ $31.24.
- Plan/authorization: Sales were effected under a Rule 10b5-1 trading plan adopted March 24, 2026 (Footnote F1).
- Conversion note: Class B common is convertible one-for-one into Class A common (Footnote F2); conversion appears to be a non-cash exchange in this filing.
- Pricing detail: The filing discloses weighted-average prices and price ranges for the grouped sales (Footnotes F4–F6) and offers to provide per-price quantities on request.
- Ownership notes: The filer disclaims beneficial ownership of shares held of record by a trust except to the extent of any pecuniary interest (Footnote F3). The filing also notes inclusion of shares to be issued in connection with RSU vesting (Footnote F7).
- Timeliness: Filing shows a July 6, 2026 submission for July 1 transactions; no late-filing flag was indicated in the summary provided.
Context
- This was a sale of converted shares (conversion + immediate open-market disposition on the same date), not a purchase. Sales under a pre-established 10b5-1 plan are typically scheduled trades and are often treated as routine rather than a real-time signal of the insider’s view.
- For retail investors, purchases typically carry more weight as a bullish signal; here the filing documents conversion and monetization of shares rather than an accumulation of new stock.